KalVista Pharmaceuticals, Inc. will be initiating a Phase 1 trial for KVD 900, the second candidate in the oral HAE portfolio. The trial commenced in December 2017, in line with KalVista’s previously stated 2017 objectives. Says Andrew Crockett, CEO of KalVista:
“2018 will be an exciting year for our HAE portfolio, with our second oral plasma kallikrein inhibitor candidate in a Phase 1 clinical trial and an anticipated regulatory filing for a third candidate before year-end.”
KVD900 is the second clinical candidate from a portfolio of oral plasma kallikrein inhibitors for potential treatment of HAE. KalVista’s strategy is to develop and evaluate multiple oral molecules in pursuit of a best-in-class therapy for HAE patients. This portfolio approach may also lead to the development of multiple molecules to address an unmet need in both prophylactic and on-demand market segments. The Phase 1 trial of KVD900 is actively screening healthy volunteers to evaluate the safety, tolerability, and exposure of the drug candidate and a plasma-based assay will be used to assess the pharmacodynamic effect of KVD900. KalVista expects to provide an update on the status and progress of the HAE portfolio, including KVD900, in mid-2018, with a goal to advance at least one additional candidate to the clinic before the end of 2018.